荃信生物-B(02509.HK):QX004N進入III期臨牀試驗及收到翰森製藥的付款
格隆匯8月5日丨荃信生物-B(02509.HK)公告,公司正在開發用於治療銀屑病(Ps)及克羅恩病(CD)的白介素23p19亞基(IL23p19)抑制劑QX004N。於2024年4月,公司與翰森製藥集團有限公司(股份代號:3692.HK)的全資附屬公司翰森(上海)健康科技有限公司就QX004N在中國內地、臺灣、香港及澳門的研發、生產及商業化訂立獨家對外授權協議。
公司董事會欣然宣佈,QX004N最近已進入III期臨牀試驗,成爲公司管線中第四個成功進入III期階段的產品。
最近,公司已收到翰森製藥根據授權協議支付的Ps III期里程碑及其他付款,共計人民幣58.0百萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.